Additionally, therapy resistance remains a hurdle in treating metastatic melanoma patients, and even though the CDK4/6 pathway is often dysregulated in melanoma patients, clinical data have suggested an intrinsic resistance of melanoma to CDK4/6 inhibitors [49–51]. This evidence concerns the gene CDK4 and melanoma.